Charcot-Marie-Tooth Disease Type X (CMTX): Comprehensive Disease Characterization Report

Report type: Disease knowledge-base entry — aggregated disease-level synthesis of primary literature and reference databases. Primary evidence base: Human clinical cohorts and case series, mouse models, and in vitro cell studies (PMIDs cited throughout).

Summary

Charcot-Marie-Tooth disease type X (CMTX) is an X-linked form of inherited peripheral neuropathy. Its dominant and prototypical subtype, CMTX1, is caused by mutations in GJB1, the gene encoding the gap-junction protein connexin-32 (Cx32), expressed by myelinating Schwann cells peripherally and by oligodendrocytes centrally. CMTX1 is the second most common form of CMT overall (after CMT1A/PMP22 duplication), accounting for roughly 7–16% of genetically diagnosed cases in most cohorts. It presents as a slowly progressive, length-dependent sensorimotor polyneuropathy with distal weakness, atrophy, sensory loss, pes cavus, and areflexia, typically beginning in the first two decades (PMID: 37284795, PMID: 35383424).

Because the disorder is X-linked, hemizygous males are affected more severely than heterozygous females, and there is characteristically no male-to-male transmission—a key pedigree clue. Electrophysiology shows "intermediate" nerve conduction velocities (~25–45 m/s in males), distinguishing CMTX1 from uniformly slowed CMT1A and normal-velocity axonal CMT2 (PMID: 15468313, PMID: 28768847). Mechanistically, loss of Cx32 abolishes the reflexive gap junctions that provide a radial diffusion pathway across the myelin sheath—approximately one million times faster than the circumferential route—leading to early axonal transport and cytoskeletal defects that precede demyelination (PMID: 9722620, PMID: 20720503). Because Cx32 is also expressed centrally, a minority of patients experience transient, reversible CNS "stroke-like" episodes, and CMTX carries an increased frequency of CNS demyelination/multiple sclerosis (PMID: 12111842, PMID: 30196252).

Life expectancy in CMTX1 is normal, and management is presently supportive (physiotherapy, orthotics, foot-deformity correction, pain management). No disease-modifying therapy is approved, but AAV9-mediated, Schwann-cell-targeted GJB1 gene replacement rescues the Gjb1-null mouse both before and after symptom onset and is the leading emerging strategy; serum neurofilament light chain (NfL) is a promising circulating biomarker of the axonal injury underlying disability (PMID: 33692503, PMID: 42017539, PMID: 40014417). The term "CMTX" is genetically heterogeneous: beyond CMTX1 (GJB1), rarer subtypes include CMTX4/Cowchock syndrome (AIFM1), CMTX5 (PRPS1), and others (PMID: 23217327).

Key Findings

1. CMTX1 is caused by GJB1/connexin-32 mutations and is the second most common form of CMT

Multiple large cohorts confirm GJB1 (connexin-32) as the causal gene for the dominant X-linked subtype (CMTX1). The largest natural-history study (387 patients / 295 families) states: "Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterized by progressive sensory and motor neuropathy with males affected more severely than females" (PMID: 37284795). That study reported 154 distinct GJB1 variants, of which 82.4% were pathogenic/likely pathogenic.

2. X-linked inheritance with males more severely affected than females

Panosyan et al. (87 males mean age 41; 73 females mean age 46) found: "Sensory-motor polyneuropathy affects both sexes, more severely in males than in females, and there was a strong correlation between age and disease burden in males but not in females" (PMID: 28768847). Record et al. confirmed males (166/319, 52%) were more severely affected at baseline (PMID: 37284795).

3. Axonal degeneration precedes demyelination

In Gjb1-null mice studied at 2–4 months (minimal demyelination), "axonal abnormalities including impaired cytoskeletal organization and defects in axonal transport precede demyelination in this mouse model of CMT1X"—with reduced large-axon diameters, neurofilament dephosphorylation, increased β-amyloid precursor protein (an axonal-damage marker), and slowed fast axonal transport (PMID: 20720503). This establishes the temporal causal chain: axonal dysfunction is upstream of demyelination.

4. CNS involvement and transient "stroke-like" episodes are a recognized feature

Cx32 is expressed by both Schwann cells and oligodendrocytes. CNS-phenotype mutants "failed to reach the cell membrane and were instead retained in the endoplasmic reticulum (A39V, T55I) or Golgi apparatus (M93V, R164Q, R183H)" (PMID: 12111842). Multiple case reports document transient stroke-like episodes with reversible corpus-callosum-splenium DWI lesions, triggered by fever, infection, exercise, altitude, or allergen exposure, resolving within hours to days (PMID: 30952033, PMID: 42477620).

5. AAV9-mediated Schwann-cell-targeted GJB1 gene therapy rescues CMT1X in mice

Kagiava et al. delivered GJB1/Cx32 under the Mpz promoter intrathecally in Gjb1-null mice; a pre- and post-onset trial "demonstrated improved motor performance and sciatic nerve conduction velocities along with improved myelination and reduced inflammation in peripheral nerve tissues," with "Blood biomarker levels… also significantly ameliorated" (PMID: 33692503). Current management remains supportive: "Symptomatic management is still the only option, but many therapeutic approaches are under investigation" (PMID: 40014417).

6. Core clinical phenotype: adolescent-onset distal weakness, atrophy, sensory loss, foot deformity

Yalcouyé et al. (Mali cohort): "Neurological examination found a distal muscle weakness and atrophy, and sensory loss, skeletal deformities, decreased or absent reflexes and steppage gait" (PMID: 35383424). Chen et al. documented a "median age of onset of 16.5 years (range: 13–30)" (PMID: 31323543). Occasional sensorineural hearing loss occurs in a variant-dependent manner (PMID: 12542510).

7. Female phenotypic variability is NOT explained by skewed X-inactivation

Bekircan-Kurt et al. analyzed X-chromosome inactivation via HUMARA in archived sural-nerve biopsies from two female CMTX1 patients (previously misdiagnosed as CIDP): "our findings suggest that XCI does not contribute to phenotypic variability in female CMTX1 patients" (PMID: 40759929). This refutes a long-standing hypothesis.

8. Intermediate conduction velocities and no male-to-male transmission are key diagnostic clues

Vondracek et al.: "All patients having the CMT phenotype and intermediate conduction velocities who are negative for CMT1A duplication/hereditary neuropathy with liability to pressure palsies (HNPP) deletion, and whose family shows a dominant trait without male-to-male transmission, should be screened for CMTX1" (PMID: 15468313).

9. Epidemiology: CMT ~1/2,500; GJB1 ~7–16% (second most common)

Milley et al. (Hungary): "alterations were most frequently found in PMP22 (40.5%), followed by GJB1 (9.2%)" (PMID: 29174527). Corroborated by Bashkortostan (13.7%) and Southern Italy cohorts (PMID: 19062535, PMID: 25429913).

10. Cx32 forms reflexive gap junctions providing a ~million-fold faster radial diffusion pathway

Balice-Gordon, Bone & Scherer: "a gap junction-mediated radial pathway may be essential for rapid diffusion between the adaxonal and perinuclear cytoplasm, since this radial pathway is approximately one million times faster than the circumferential pathway" (PMID: 9722620). Scherer's review confirms: "Reflexive gap junctions, comprising connexin32 and at least one other connexin protein, form a radial pathway for the diffusion of ions and small molecules directly across the myelin sheath" (PMID: 10586239).

11. "CMTX" is genetically heterogeneous

Beyond CMTX1 (~90% of X-linked CMT), rarer subtypes exist. Rinaldi et al.: "Cowchock syndrome (CMTX4) is a slowly progressive X-linked recessive disorder with axonal neuropathy, deafness, and cognitive impairment" caused by AIFM1 variants (PMID: 23217327, PMID: 26173962). Others: CMTX5 (PRPS1), CMTX2/3, CMTX6 (PDK3).

12. CMTX is associated with increased CNS inflammatory demyelination / MS

Koutsis et al. (70 CMTX patients over 20 years): "The resulting 20-year MS incidence (4.3%) differed significantly from the highest background 20-year MS incidence ever reported from Greece (p=0.00039)"; 10/18 cases had splenium hyperintensity vs 0 controls (p=0.0002) (PMID: 30196252).

13. Natural history: slow progression quantified by CMTES; c.-17G>A has a distinct milder phenotype

Record et al. used the CMT Examination Score (CMTES) for longitudinal tracking. "Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline", and genotype analysis "suggested c.-17G>A produces" a distinct milder phenotype (PMID: 37284795).

14. Serum NfL is an emerging circulating biomarker of axonal injury

In the Gjb1-null model, gene therapy significantly ameliorated blood NfL alongside functional/histological rescue (PMID: 33692503). In human CMT-spectrum carriers, "All carriers exhibited elevated serum NfL" (PMID: 42017539).

Mechanistic Model / Interpretation

CMTX1 is best understood as a Schwann-cell-autonomous defect that becomes a functional axonopathy. Loss or mistrafficking of connexin-32 removes the reflexive gap junctions that create a radial "shortcut" for ions and metabolites across the myelin sheath—a pathway ~10⁶-fold faster than diffusion around the myelin spiral (PMID: 9722620). The immediate consequence is failure of adaxonal homeostasis, producing cytoskeletal disorganization and slowed axonal transport before myelin breaks down (PMID: 20720503). Over years, demyelination and secondary axonal degeneration accumulate distally, generating the length-dependent clinical picture; serum NfL is the circulating footprint of that axonal loss.

Two features flow from Cx32's dual expression and X-linkage. First, oligodendrocyte Cx32 loss makes central myelin metabolically fragile, so stressors (fever, exercise, altitude, allergen exposure) can precipitate reversible CNS lesions, and CMTX carries excess CNS demyelination/MS (PMID: 12111842, PMID: 30196252). Second, X-linkage dictates that hemizygous males are uniformly and more severely affected while heterozygous females are variable—variability that is not explained by skewed X-inactivation (PMID: 40759929). The predominantly loss-of-function nature of the disease is exactly why gene replacement is compelling: restoring Schwann-cell Cx32 improves function, conduction, myelination, and biomarkers in vivo, both before and after onset (PMID: 33692503).

 GJB1 mutation (hemizygous male / heterozygous female)
│
▼
 Loss / mistrafficking of Connexin-32
│
├──────────► Oligodendrocytes (CNS): stress-triggered reversible
│            white-matter dysfunction ("stroke-like episodes"); ↑MS risk
▼
 Loss of reflexive gap junctions in Schwann cells
 (Schmidt-Lanterman incisures, paranodes)
│
▼
 Loss of fast radial diffusion pathway (~10^6× faster than circumferential)
│
▼
 Impaired adaxonal ion/metabolite homeostasis
│
▼
 EARLY: axonal cytoskeletal disorganization + slowed axonal transport
│  (neurofilament dephosphorylation, ↑β-APP)
▼
 LATER: demyelination  →  secondary axonal degeneration
│
▼
 Length-dependent distal weakness, atrophy, sensory loss, areflexia

Full Disease Characterization (15 Sections)

1. Disease Information

Overview. CMTX is a group of X-linked inherited peripheral neuropathies; the most common and prototypical form is CMTX1, caused by pathogenic variants in GJB1 (connexin-32/Cx32). It is a progressive length-dependent sensorimotor polyneuropathy with mixed demyelinating and axonal ("intermediate") features, in which males are affected more severely than females, and is the second most common form of CMT overall after CMT1A (PMID: 37284795, PMID: 29174527).

Key identifiers.

Synonyms. X-linked Charcot-Marie-Tooth disease type 1; CMTX1; CMT1X; hereditary motor and sensory neuropathy, X-linked (HMSN-X / HMSN 1X); X-linked dominant CMT; connexin-32 neuropathy.

Genetic heterogeneity of "CMTX." CMTX1 (GJB1) accounts for ~90% of X-linked CMT and is X-linked dominant with demyelinating/intermediate physiology. Rarer, often syndromic subtypes include CMTX4 (AIFM1; Cowchock syndrome)—X-linked recessive, axonal, with deafness and cognitive impairment (PMID: 23217327, PMID: 26173962)—plus CMTX5 (PRPS1), CMTX2/3, and CMTX6 (PDK3) (PMID: 41557339).

Data provenance. Derived from aggregated, disease-level resources (OMIM, Orphanet, peer-reviewed cohorts, case series, and mechanistic studies), not individual EHR data.

2. Etiology

Primary cause (genetic, monogenic). Loss-of-function / dominant-negative / trafficking-defective mutations in GJB1/Cx32 on Xq13.1. Over 150 variants are reported; one large cohort documented 154 variants across 295 families (PMID: 37284795). Both hemizygous males and heterozygous females develop disease.

Genetic risk factors. Being hemizygous male for a pathogenic GJB1 variant confers the highest burden. No consistent modifier loci are established; genotype–phenotype correlations are generally weak, though the promoter variant c.-17G>A produces a distinct milder phenotype (PMID: 37284795).

Environmental / triggering factors. CMTX1 is not environmentally caused, but transient CNS episodes are precipitated by fever, infection, vigorous exercise, high altitude/hyperventilation, and allergen/pollen exposure (PMID: 42477620, PMID: 30952033). Age and male sex are the strongest modifiers of peripheral severity (PMID: 28768847).

Protective factors. No validated genetic/environmental protective factors. In females, one normal GJB1 allele generally yields milder disease—but not through skewed X-inactivation (PMID: 40759929).

Gene–environment interactions. Metabolic/thermal stress precipitating reversible oligodendrocyte dysfunction in Cx32-mutant individuals is the main documented GxE interaction (PMID: 42477620).

3. Phenotypes

Core peripheral neuropathy (symmetric, length-dependent, adolescent onset):

Yalcouyé et al.: "The predominant starting symptom was tingling, and the chief complaint was gait difficulty. Neurological examination found a distal muscle weakness and atrophy, and sensory loss, skeletal deformities, decreased or absent reflexes and steppage gait" (PMID: 35383424). Median onset ~16.5 years (range 13–30) (PMID: 31323543). Severity mild–moderate in females, moderate–severe in males, strongly age-dependent in males; high intra-/inter-familial variability.

Quality-of-life impact. CMT substantially reduces QoL; a survey of rare neurological conditions including CMT reported EQ-5D index 0.2–0.44, with frequent pain, anxiety/depression, and problems with mobility, self-care, and usual activities (PMID: 23001492).

4. Genetic / Molecular Information

Causal gene. GJB1 (connexin-32/Cx32), Xq13.1; a four-transmembrane gap-junction protein forming hexameric connexons.

Pathogenic variants. - Classes: predominantly missense (majority), plus nonsense, frameshift (c.423delC), splice-site, small in/dels, whole-gene deletions, and 5′UTR/promoter (c.-17G>A) variants (PMID: 37284795, PMID: 12542510). Representative: p.Arg22Gln, p.Pro87Ala, p.Ile127Ser/Thr, p.Arg164Gln, p.Arg183Cys/His, p.Glu186Lys, p.Glu208Gly. - Classification (ACMG/AMP): ~82.4% P/LP, remainder VUS (PMID: 37284795). - Allele frequency: absent/ultra-rare in gnomAD. - Origin: germline, X-linked; not somatic. - Functional consequence: mixed—loss of function (deletions → peripheral-only disease), dominant-negative, and trafficking defects (ER/Golgi retention for CNS mutants; PMID: 12111842).

Genotype–phenotype. Generally weak; deletion/null alleles cause peripheral-only disease, whereas mistrafficking mutants associate with CNS phenotypes; c.-17G>A is milder (PMID: 12542510, PMID: 37284795). VUS behave like P/LP at baseline, supporting reclassification (PMID: 37284795).

Modifier genes / epigenetics / chromosomal. No firm modifiers; female variability is not from skewed XCI (PMID: 40759929). Whole-GJB1 deletions are the largest lesions; no characteristic cytogenetic rearrangements.

5. Environmental Information

• Environmental factors: no causal toxin/pollution; physiological stressors (fever, infection, exercise, altitude, allergens) trigger transient CNS episodes (PMID: 42477620, PMID: 30952033).
• Lifestyle: no established dietary/smoking/alcohol risk; deconditioning worsens function; avoid neurotoxic drugs (e.g., vincristine) in any CMT.
• Infectious agents: none cause CMTX1; infections act only as nonspecific triggers.

6. Mechanism / Pathophysiology

Normal Cx32 function. Cx32 forms reflexive gap junctions in non-compact myelin (paranodes, Schmidt-Lanterman incisures), creating a radial diffusion pathway ~10⁶× faster than the circumferential route (PMID: 9722620, PMID: 10586239). Partial redundancy from other connexins may contribute to variability.

Causal chain. Pathogenic GJB1 variant → loss/dysfunction of Cx32 reflexive gap junctions → impaired Schwann-cell–axon radial diffusion/metabolic support → early axonal cytoskeletal and transport defects → demyelination and secondary axonal degeneration → length-dependent denervation → weakness/atrophy/sensory loss.

Upstream vs downstream. In Gjb1-null mice with minimal demyelination, "axonal abnormalities… precede demyelination" (PMID: 20720503); electrophysiology shows "primary demyelinating neuropathy with secondary axonal loss" (PMID: 15468313). This supports the "functional axonopathy" model (PMID: 16775378).

Protein dysfunction. CNS-phenotype mutants (A39V, T55I → ER; M93V, R164Q, R183H → Golgi) "failed to reach the cell membrane" (PMID: 12111842).

Cells & processes (GO/CL). Myelinating Schwann cell (CL:0002573), oligodendrocyte (CL:0000128); myelination (GO:0042552), gap-junction assembly/cell-cell signaling (GO:0007267), axonal transport (GO:0008088), connexin complex (GO:0005922); secondary neuroinflammation reduced by gene therapy (PMID: 33692503).

Immune involvement. Not autoimmune, but secondary neuroinflammation occurs; an emerging epidemiological CMTX–MS association (20-yr MS incidence 4.3%, p=0.00039) suggests Cx32 loss may predispose to CNS inflammatory demyelination (PMID: 30196252).

Biomarkers. Blood NfL is elevated and tracks disease/therapy in the model (PMID: 33692503) and in human carriers (PMID: 42017539).

7. Anatomical Structures Affected

• Organ/system: Peripheral nervous system (UBERON:0000010) primary; CNS white matter (UBERON:0002316) secondary/transient; musculoskeletal (distal atrophy, foot deformity).
• Nerves: distal > proximal—sural, peroneal/fibular, median, ulnar, radial (PMID: 28768847); sciatic (UBERON:0001322).
• Tissue/cell: myelinating Schwann cells (CL:0002573); oligodendrocytes (CL:0000128); secondary skeletal muscle denervation.
• Subcellular (GO CC): connexin complex/gap junction (GO:0005922) at non-compact myelin; mutant protein in ER (GO:0005783) and Golgi (GO:0005794); axonal neurofilaments (GO:0005882).
• Localization/laterality: bilateral, symmetric, length-dependent peripheral involvement; CNS lesions often symmetric, favoring corpus callosum splenium and centrum semiovale (PMID: 42477620).

8. Temporal Development

• Onset: typically first–second decade (median ~16.5 y; PMID: 31323543); insidious/chronic. Transient CNS episodes can be an acute/subacute presenting event, sometimes in childhood.
• Progression: slowly progressive over decades; strong age–severity correlation in males, not females (PMID: 28768847).
• Course: peripheral neuropathy chronic-progressive, lifelong; CNS episodes episodic and reversible (hours–days).
• Critical windows: pre- and post-onset gene therapy both improved outcomes in mice, implying a therapeutic window extending beyond onset (PMID: 33692503).

9. Inheritance and Population

• Inheritance: X-linked (dominant with intermediate female expression); hallmark no male-to-male transmission (PMID: 15468313). Affected fathers → all daughters (carriers), no sons; carrier mothers → 50% of children.
• Penetrance: near-complete in hemizygous males; variable/incomplete in heterozygous females.
• Expressivity: highly variable, even within families (PMID: 35383424).
• Anticipation: none (not a repeat expansion).
• Founder effects: regional alleles exist (e.g., Pro87Ala in Bashkortostan with a shared haplotype; PMID: 19062535).
• Consanguinity: not relevant (X-linked).
• Epidemiology: overall CMT ~1/2,500 (PMID: 29174527); GJB1 ~9% of CMT (second most common), ~13.7% regionally → estimated CMTX1 prevalence ~1.3–6/100,000.
• Geography: worldwide, including a sub-Saharan African cohort (Mali; PMID: 35383424); no strong ethnic predilection.
• Sex ratio: both sexes affected; males more severely (PMID: 28768847).

10. Diagnostics

• Electrophysiology (key): "intermediate" motor conduction velocities (~25–45 m/s), demyelinating + secondary axonal loss, often non-uniform slowing; females less slowed (PMID: 15468313, PMID: 28768847).
• Clinical/pedigree criteria: CMT phenotype + intermediate NCV + negative PMP22 dup/HNPP deletion + dominant inheritance without male-to-male transmission → screen GJB1 (PMID: 15468313).
• Genetic testing (confirmatory): single-gene GJB1 sequencing or NGS CMT panel / WES (PMID: 39428786); MLPA first to exclude PMP22 dosage changes; dosage methods for whole-gene deletions.
• Nerve biopsy (not routine): demyelination, remyelination, onion bulbs, axonal loss (PMID: 12542510).
• Imaging: brain MRI during CNS episodes shows reversible DWI-restricted white-matter lesions (splenium, centrum semiovale); MRA/MRV normal (PMID: 42477620, PMID: 30196252).
• Audiology: when hearing loss suspected (PMID: 41557339).
• Biomarker: serum NfL (axonal degeneration), normalized by gene therapy in model and elevated in human carriers (PMID: 33692503, PMID: 42017539).
• Differential diagnosis: CMT1A (uniform slowing), MPZ-CMT, CIDP (females with conduction block often misdiagnosed; PMID: 40759929); during CNS episodes: stroke, MELAS, ADEM, MS.
• Screening: cascade/carrier testing of at-risk relatives; prenatal/PGT for known variants.

11. Outcome / Prognosis

• Survival/mortality: normal/near-normal life expectancy; not directly life-limiting.
• Morbidity/disability: progressive distal weakness, foot deformity, gait impairment, hand dexterity loss, neuropathic pain, fatigue; most patients remain ambulatory (often with AFOs); males accrue greater disability with age (PMID: 28768847).
• Quality of life: substantially reduced (EQ-5D 0.2–0.44; PMID: 23001492).
• Complications: falls/fractures, foot ulceration, contractures; transient CNS episodes; possible increased MS risk (PMID: 30196252); hearing loss in a subset.
• Prognostic factors: male sex, older age (PMID: 28768847); longitudinal change captured by CMTES (PMID: 37284795); c.-17G>A predicts milder course.

12. Treatment

• Disease-modifying therapy: none approved — "Symptomatic management is still the only option" (PMID: 40014417).
• Emerging gene therapy: AAV9-Mpz.GJB1 (Schwann-cell-targeted, intrathecal) rescued Gjb1-null mice pre- and post-onset with improved motor performance, conduction, myelination, reduced inflammation, and improved blood biomarkers (PMID: 33692503) (NCIT: Gene Therapy).
• Supportive/rehabilitative (standard of care): physical/occupational therapy, ankle-foot orthoses, stretching, exercise, assistive devices (NCIT: Physical Therapy, Occupational Therapy, Orthotic Device).
• Symptom management: neuropathic pain control (gabapentinoids, duloxetine, tricyclics), fatigue management, foot care.
• Surgical: corrective foot surgery (osteotomy, tendon transfer, arthrodesis) for disabling deformity.
• Sensorineural hearing loss: cochlear implantation beneficial in selected patients, best early (PMID: 41557339).
• Cautions: avoid neurotoxic agents (vincristine, etc.).

13. Prevention

• Primary: not preventable (monogenic); genetic counseling and reproductive options (prenatal diagnosis, PGT) for known GJB1 variants.
• Secondary: cascade genetic screening of at-risk relatives; early identification enables avoidance of neurotoxic drugs and early orthotics/PT.
• Tertiary: rehabilitation, orthotics, foot care, pain management to prevent falls, deformity, ulceration (PMID: 40014417).
• Trigger avoidance: manage fever, extreme exertion, high altitude in patients with CNS episodes (PMID: 42477620).
• Counseling: X-linked recurrence-risk education (no male-to-male transmission).
• Immunization/public health/prophylaxis: not applicable.

14. Other Species / Natural Disease

• Taxonomy: Mus musculus (NCBI Taxon 10090); Homo sapiens (9606).
• Ortholog: mouse Gjb1/connexin-32 (NCBI Gene 14618); highly conserved.
• Natural disease: no well-characterized spontaneous CMTX1-equivalent connexin-32 neuropathy is catalogued in companion animals in OMIA; studied primarily via engineered rodent models.
• Comparative biology: Cx32 gap-junction biology and myelin architecture are conserved across mammals.
• Zoonotic potential: none (genetic disease).

15. Model Organisms

• Principal model: Gjb1-null (Cx32 knockout) mouse—recapitulates progressive demyelinating peripheral neuropathy with early axonal changes (PMID: 20720503) and impaired conduction; used for natural-history and therapy studies (PMID: 33692503).
• Model types: knockout; human-mutation knock-in/transgenic lines; cell models (HeLa / communication-incompetent cells transfected with WT/mutant Cx32 for trafficking assays; PMID: 12111842).
• Phenotype recapitulation: good for peripheral demyelination, axonal transport defects, conduction slowing, elevated NfL, neuroinflammation, and treatment response.
• Limitations: milder CNS involvement; does not fully model human transient stroke-like episodes or the male–female severity dichotomy.
• Applications: mechanistic dissection (axon vs myelin), preclinical gene therapy, biomarker development.
• Resources: MGI (Gjb1), IMPC/IMSR, Cellosaurus.

Evidence Base

Ontology term suggestions (summary). MONDO:0010674; OMIM 302800. HPO: HP:0002460 (distal weakness), HP:0003693 (distal amyotrophy), HP:0001761 (pes cavus), HP:0106487 (impaired distal sensation), HP:0003401 (paresthesia), HP:0001265 (areflexia), HP:0003376 (steppage gait), HP:0000407 (SNHL), HP:0002401 (stroke-like episode). GO: GO:0042552 (myelination), GO:0007267 (cell-cell signaling), GO:0008088 (axonal transport), GO:0005922 (connexin complex), GO:0005783 (ER), GO:0005794 (Golgi). CL: CL:0002573 (myelinating Schwann cell), CL:0000128 (oligodendrocyte). UBERON: UBERON:0000010 (PNS), UBERON:0002316 (white matter), UBERON:0001322 (sciatic nerve). NCIT: Gene Therapy, Physical Therapy, Occupational Therapy, Orthotic Device, Cochlear Implant.

Limitations and Knowledge Gaps

1. No primary experimental dataset was analyzed; conclusions rest on published cohorts, case reports, and mechanistic studies (evidence types: human clinical, mouse model, in vitro, computational).
2. Prevalence estimates for CMTX1 specifically are indirect (CMT-wide prevalence × GJB1 fraction).
3. Human molecular profiling is sparse—transcriptomic/proteomic/metabolomic maps of human CMTX1 nerve are limited; much mechanistic detail derives from the Gjb1-null mouse, which does not fully model CNS episodes, the MS-association, or intermediate CVs.
4. Female-variability mechanism remains unexplained after XCI was refuted (PMID: 40759929); modifier genes/epigenetics are uncharacterized.
5. Weak genotype–phenotype correlation limits variant-specific prognostication (beyond c.-17G>A and CNS-mutant trafficking).
6. CNS/stroke-like episodes and MS association derive largely from case series (lower evidence level).
7. No approved disease-modifying therapy; gene-therapy evidence is preclinical, and serum NfL requires CMTX1-specific longitudinal validation as a surrogate endpoint.
8. No well-documented naturally occurring animal counterpart exists; comparative data are thin.

Proposed Follow-up Experiments / Actions

1. Advance AAV9-GJB1 gene therapy toward clinical trials, using CMTES and serum NfL as co-primary endpoints and leveraging the demonstrated pre-/post-onset efficacy window (PMID: 33692503).
2. Prospective longitudinal NfL study in genotyped CMTX1 males and females to validate NfL as a progression/response biomarker and correlate with CMTES.
3. Single-cell / spatial transcriptomics of human (or humanized-model) peripheral nerve to map Schwann-cell and axonal molecular changes in situ and confirm upstream vs. downstream events.
4. Search for genetic/epigenetic modifiers of female severity now that skewed XCI is excluded—candidate modifier screens and family-based studies.
5. Systematic genotype–phenotype cataloguing (variant class × CNS involvement × severity) integrating trafficking assays to refine ACMG classification and reclassify VUS.
6. Prospective natural-history and MS-surveillance cohort to clarify the CMTX–MS relationship and define management for CNS episodes and triggers.
7. Consolidate rare CMTX subtype registries (AIFM1, PRPS1, PDK3) to distinguish them diagnostically and prognostically from CMTX1.

Evidence Source Types

Human clinical cohorts/case series: PMIDs 37284795, 28768847, 31323543, 35383424, 12542510, 30952033, 42477620, 30196252, 39428786, 41557339, 23001492, 29174527, 19062535, 15468313, 40759929, 23217327, 26173962, 25429913, 42017539. Mouse in vivo: 20720503, 33692503. In vitro cell biology: 12111842, 9722620. Reviews: 16775378, 40014417, 10586239.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:9722620 (10 mentions) - Functional gap junctions in the schwann cell myelin sheath.
• shared terms: cx32
• PMID:10586239 (6 mentions) - Nodes, paranodes, and incisures: from form to function.
• shared terms: axonal

Weighed against this report's own most characteristic terms: gjb1, cns, gene, female, cmtx1, male, episode, axonal, cmt, cx32, disease, therapy, cohort, variant, phenotype, loss, neuropathy, x-linked, patient, transient.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0010674 (2 mentions) - the report calls it "MONDO"; MONDO calls it mucopolysaccharidosis type 2
• HP:0002460 (2 mentions) - the report calls it "Sign", "distal weakness"; HP calls it Distal muscle weakness
• HP:0003693 (2 mentions) - the report calls it "Manifestation", "distal amyotrophy"; HP calls it Distal amyotrophy
• HP:0003401 (2 mentions) - the report calls it "Symptom", "paresthesia"; HP calls it Paresthesia
• HP:0001761 (2 mentions) - the report calls it "Manifestation", "pes cavus"; HP calls it Pes cavus
• HP:0001265 (2 mentions) - the report calls it "Sign", "areflexia"; HP calls it Hyporeflexia
• HP:0003376 (2 mentions) - the report calls it "Sign", "steppage gait"; HP calls it Steppage gait
• HP:0000407 (2 mentions) - the report calls it "Sign/lab", "SNHL"; HP calls it Sensorineural hearing impairment

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0106487 (2 mentions), reported as "Sign", "impaired distal sensation" - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0002401 (2 mentions) - the report calls it "Sign (episodic)", "stroke-like episode"; HP calls it Stroke-like episode
• CL:0002573 (3 mentions) - the report calls it "Tissue/cell: myelinating Schwann cells", "myelinating Schwann cell"; CL calls it Schwann cell**
• GO:0008088 (2 mentions) - the report calls it "axonal transport"; GO calls it axo-dendritic transport, and lists "axonal transport" among its other names
• UBERON:0000010 (2 mentions) - the report calls it "Peripheral nervous system", "Organ/system: Peripheral nervous system", "PNS"; UBERON calls it peripheral nervous system
• UBERON:0002316 (2 mentions) - the report calls it "CNS white matter", "white matter"; UBERON calls it white matter, and lists "CNS white matter" among its other names
• GO:0005783 (2 mentions) - the report calls it "ER"; GO calls it endoplasmic reticulum, and lists "ER" among its other names
• GO:0005794 (2 mentions) - the report calls it "Golgi"; GO calls it Golgi apparatus, and lists "Golgi" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• HP:0002460 - called "Sign", "distal weakness"
• HP:0003693 - called "Manifestation", "distal amyotrophy"
• HP:0106487 - called "Sign", "impaired distal sensation"
• HP:0003401 - called "Symptom", "paresthesia"
• HP:0001761 - called "Manifestation", "pes cavus"
• HP:0001265 - called "Sign", "areflexia"
• HP:0003376 - called "Sign", "steppage gait"
• HP:0000407 - called "Sign/lab", "SNHL"
• HP:0002401 - called "Sign (episodic)", "stroke-like episode"
• CL:0002573 - called "Tissue/cell:** myelinating Schwann cells", "myelinating Schwann cell"
• UBERON:0000010 - called "Peripheral nervous system", "Organ/system: Peripheral nervous system", "PNS"
• UBERON:0002316 - called "CNS white matter", "white matter"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.